Drug Disc. and Pharma. Analysis: New Test Available for Faster Results in Diagnosis of Sepsis
Apr 05 2006 Read 5560 Times
The LightCycler SeptiFast test, a new rapid and reliable test for the detection and identification of 25
different sepsis-causing pathogens. The test, which has been developed by Roche Diagnostics, is the world's first PCR-based test of this kind, and can successfully recognise the infectious pathogens
responsible for approximately 90% of all sepsis cases.
Over 23,000 patients in the UK develop severe sepsis each year and with a hospital mortality rate of 45%, for over 10,000 of these people it proves fatal. This equates more than 27 deaths per day. Despite
improvements in its medical management, sepsis still constitutes one of the greatest challenges in intensive care medicine, with up to 26% of patients being given inappropriate treatment.
The LightCycler SeptiFast test has the major advantage of being able to detect and identify both bacterial and fungal sepsis pathogens in less than six hours. This offers a significant improvement over the
traditional blood culture methods which can take up to two to five days and even then there is a positive test rate of less than 20% for patients with sepsis. This is an important time saving for targeted
medical treatment, as only after pathogens are correctly identified can targeted therapy using a specific antibiotic begin.
different sepsis-causing pathogens. The test, which has been developed by Roche Diagnostics, is the world's first PCR-based test of this kind, and can successfully recognise the infectious pathogens
responsible for approximately 90% of all sepsis cases.
Over 23,000 patients in the UK develop severe sepsis each year and with a hospital mortality rate of 45%, for over 10,000 of these people it proves fatal. This equates more than 27 deaths per day. Despite
improvements in its medical management, sepsis still constitutes one of the greatest challenges in intensive care medicine, with up to 26% of patients being given inappropriate treatment.
The LightCycler SeptiFast test has the major advantage of being able to detect and identify both bacterial and fungal sepsis pathogens in less than six hours. This offers a significant improvement over the
traditional blood culture methods which can take up to two to five days and even then there is a positive test rate of less than 20% for patients with sepsis. This is an important time saving for targeted
medical treatment, as only after pathogens are correctly identified can targeted therapy using a specific antibiotic begin.
Digital Edition
Lab Asia December 2019
December 2019
In This Edition Mass Spectrometry & Spectroscopy - Translating Proteomic MALDi Tissue Typing to Clinical Pathology - Fusion Protein Complexes Analysed by CG-MALS - Non-equivalent, Multivalen...
View all digital editions
Events
Dec 13 2019 Kathmandu, Nepal
Jan 25 2020 San Diego, CA, USA
Jan 27 2020 Dubai, UAE
Jan 29 2020 Tokyo, Japan
Jan 29 2020 Ghent, Belgium
Reader comments
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.